Back

Ceftazidime-Avibactam Resistance in Escherichia coli Primarily Mediated by blaNDM-5 with Emergent Ceftazidime-Avibactam/Aztreonam Resistance Linked to blaCMY-42 Variants

Shropshire, W. C.; Borjan, J.; Khan, A.; Young, A.; Chung, J. K.; Wu, C.-T.; Manzanares, A.; Bhatti, M. M.; Vuong, N. N.; Handley, G.; Spallone, A.; Chemaly, R. F.; Shelburne, S.

2025-12-07 infectious diseases
10.64898/2025.12.05.25341718 medRxiv
Show abstract

Ceftazidime-avibactam (CZA) has revolutionized care for carbapenem-resistant Enterobacterales infections, yet increasing New Delhi metallo-{beta}-lactamase (NDM) prevalence has driven use of CZA plus aztreonam (CZA/ATM). We performed a comprehensive analysis of CZA-resistant Escherichia coli (CZA-R-Ec) at a tertiary cancer center (2017-2024) by integrating clinical data, comparative genomics, and CZA/ATM susceptibility testing. CZA-R-Ec were isolated from forty-eight unique patients of whom 28 (58%) had confirmed infection. Oxford Nanopore Technologies long-read sequencing performed on 34 isolates from unique patients showed a diverse population enriched for ST167 (35%). Most sequenced isolates carried blaNDM-5 (26/34, 76%); among blaNDM-5 strains, 88% (23/26) harbored PBP3 YRI(K/N) insertions. Eleven isolates (32%) carried blaCMY variants, predominantly blaCMY-42. BlaNDM-5 and blaCMY genes were largely plasmid-borne (IncF-type and IncI-{gamma}/K1) in distinct genomic contexts. Among 32 confirmed CZA-R and ATM-R index isolates, 21 (66%) were CZA/ATM synergy positive to CZA/ATM (MIC[≤]4 {micro}g/mL; SYN+). Compared to patients with SYN+ strains, patients with SYN-isolates (CZA/ATM MIC>4 {micro}g/mL) were significantly more likely to have had a prior E. coli infection (73% vs. 0%, P-value=1.6x10-5). SYN- isolates were strongly associated with blaCMY carriage (81% vs 9% in SYN+; adjusted P-value=4x10-4). Among 18 confirmed CZA-R-Ec bacteremias, 15 carried blaNDM; 14/15 (92%) received CZA/ATM and all responded clinically. In conclusion, CZA-R-Ec at our center are dominated by PBP3-insertion, blaNDM-5-positive lineages, for which CZA/ATM retains substantial in vitro activity and clinical efficacy. However, recent carbapenem exposure and prior E. coli infection identifies patients at risk for CZA/ATM non-synergy, frequently linked to blaCMY-42 variant positive isolates.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.